Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19

,

    Liver Research
    |September 1, 2020
    PubMed

    Insights

    A multidisciplinary, individualized approach significantly reduces mortality in severe COVID-19 patients. This strategy involves close monitoring and timely interventions for better outcomes.

    Area of Science:

    • Critical Care Medicine
    • Infectious Diseases
    • Pulmonology

    Background:

    • Severe/critical COVID-19 cases have a high mortality rate (up to 61.5%), particularly in elderly patients with comorbidities.
    • SARS-CoV-2 damages multiple organs, including lungs, liver, immune system, and vasculature, leading to decreased organ function and accelerated disease progression.
    • Effective management requires accurate disease prediction and timely interventions to mitigate mortality.

    Purpose of the Study:

    • To evaluate the effectiveness of a multidisciplinary, three-dimensional, individualized management strategy for severe/critical COVID-19 patients.
    • To reduce mortality rates and improve cure rates in this high-risk patient population.

    Main Methods:

    • Implementation of a "multidisciplinary three-dimensional management, individualized comprehensive plan" for severe/critical COVID-19 patients.
    • Involvement of a multidisciplinary team (MDT) including critical care, infectious disease, respiratory, and other specialists.
    • "Round-the-clock rounds management" for close observation, timely evaluation, and rapid intervention.

    Main Results:

    • The MDT treated 77 severe/critical COVID-19 cases (average age 63.8 years, 68.8% with comorbidities).
    • The treatment resulted in a significantly lower mortality rate (2.6%) and shorter hospital stay (22 days) compared to literature.
    • A high cure rate of 84.4% was observed among severe cases.

    Conclusions:

    • A multidisciplinary, three-dimensional, and individualized comprehensive treatment plan is effective in reducing mortality and improving cure rates for severe/critical COVID-19.
    • This approach enables accurate disease progression prediction and timely interventions, crucial for managing high-risk patients.
    • The strategy highlights the importance of integrated care involving various medical specialties for optimal COVID-19 patient outcomes.

    Related Concept Videos

    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    637
    Acute Respiratory Failure-III01:30

    Acute Respiratory Failure-III

    Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
    590
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    134
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    476
    Chronic Obstructive Pulmonary Disease-V: Management01:29

    Chronic Obstructive Pulmonary Disease-V: Management

    Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
    Smoking Cessation
    2.9K
    Acute Respiratory Failure-II01:21

    Acute Respiratory Failure-II

    Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
    The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
    856